Human Placenta Extract

Human placenta extract, sometimes abbreviated HPE, is a biological preparation made from human placental tissue collected after childbirth ^[1]. The placenta is processed, commonly by enzymatic hydrolysis, into an extract that concentrates small molecules such as amino acids, peptides, nucleic acids, and a variety of growth factors and cytokines while removing cells and larger structures ^[5]. Related preparations are made from the placentas of other species, and porcine placental extract in particular is widely used as an oral alternative ^[2].

The therapeutic use of placental extract carries a long history in East Asian medicine, and injectable human placenta hydrolysates have been marketed for decades in countries such as Korea and Japan under regulated brand names ^[2]. In these settings the extract has been applied to a broad set of complaints, including menopausal symptoms, chronic fatigue, chronic liver disease, and disorders of skin pigmentation ^[1]. Outside these regions its medical use is far less common, and placenta-derived materials appear more often in cosmetics than in approved medicines.

Interest in placental extract stems from the placenta's natural role as a tissue rich in signaling molecules that support growth and repair during pregnancy ^[5]. Analyses of placental and related amniotic preparations have identified numerous growth factors and cytokines involved in inflammation and wound healing, which is the biological rationale offered for effects on tissue regeneration and recovery ^[5]. The precise composition varies with the source tissue and the method of processing.

Clinical research on human placenta extract is limited and consists mostly of small trials. A randomized, placebo-controlled study in middle-aged Korean women reported that injections of human placental extract reduced menopausal symptoms and fatigue and raised estradiol levels over the course of treatment, without changing cardiovascular risk factors ^[1]. Because human placental extract is invasive to administer, later trials have often tested oral porcine placental extract as a substitute, with several randomized studies reporting modest improvements in menopausal symptom scores, particularly within certain subgroups ^[2][3][4]. Investigators generally describe the evidence base as preliminary and call for larger, better-controlled studies ^[1].

Regulatory status varies widely by country. In parts of East Asia, injectable human placenta hydrolysate is a regulated prescription product, whereas in many other jurisdictions placenta-derived extracts are treated as cosmetic ingredients or unapproved supplements rather than licensed drugs ^[2]. Because the material is of human origin, considerations around sourcing, screening for infectious agents, and processing are important to its safety profile. Placental extracts are encountered as injectable ampoules, oral capsules, and topical cosmetic preparations.

Human placenta extract is a prescription, clinic administered product and is not approved as a drug by the US FDA. Because it comes from human tissue, there is a theoretical risk of transmitting infection, and in Japan people who have received Laennec or Melsmon are permanently barred from donating blood as a precaution against prion disease. Real world side effects are usually mild and local; injection site pain, redness, swelling and occasional allergic or hypersensitivity reactions. It should be avoided in pregnancy and breastfeeding and in anyone with a known allergy to the preparation. Quality and sterility depend heavily on the manufacturer.

The therapeutic use of placental tissue traces to the tissue therapy pioneered by the Soviet ophthalmologist Vladimir Filatov in the 1930s, who proposed that preserved biological tissues released "biogenic stimulators" capable of aiding recovery. Modern standardized human placenta extracts emerged principally in Japan, where hydrolyzed preparations were developed and approved for specific medical indications; the injectable product Laennec, named in honor of the French physician Rene Laennec, has long been marketed for chronic liver disease, while Melsmon has been used for menopausal and climacteric complaints.

Manufacturing concentrates the amino acids, peptides, nucleic acids, and growth factors naturally present in placental tissue through enzymatic hydrolysis and rigorous viral-inactivation steps. Clinical use has remained concentrated in Korea and Japan, where prescribing traditions and regulatory acceptance differ substantially from those in Western countries. Rigorous controlled research is comparatively limited, though a small number of randomized trials have examined menopausal symptom relief. Its status thus reflects a long empirical history combined with a still-developing evidence base.

Human placenta extract enjoys a durable reputation in parts of East Asia as a restorative preparation, valued for its rich concentration of naturally occurring peptides and growth factors. It is best known for menopausal symptom relief, and a randomized, double-blind, placebo-controlled trial in 108 women found that it reduced Kupperman Index scores significantly more than placebo, with a favorable safety and tolerability profile. A 2025 systematic review of placental extract trials likewise concluded that both human and porcine preparations appear to offer genuine benefit for menopausal symptoms while being well tolerated.

Enthusiasts also value its reputed roles in fatigue, skin quality, and tissue recovery, reflecting the broad biological activity of its constituents. It is important to note honestly that much of the clinical literature involves small studies and that mechanisms remain incompletely defined. For those drawn to a biologically complex, traditionally esteemed preparation, it remains an intriguing option best approached with realistic expectations.